Rekvina Laboratories Ltd

Fri 4/09/2026,15:16:0 | BSE : VINRKLB

₹53.831.05 (1.99%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 53.83

Previous Close

₹ 52.78

Volume

24320

Mkt Cap ( ₹ Cr)

₹ 32.45

High

₹ 53.83

Low

₹ 53.83

52 Week High

₹ 53.83

52 Week Low

₹ 6.75

Book Value Per Share

₹ -2.24

Dividend Yield

₹ 0.00

Face Value

₹₹5.00

What's Your Call?

Collective community sentiment on Rekvina Laboratories Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Rekvina Laboratories Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Rekvina Laboratories - Reg. 34 (1) Annual Report.

    3 Sep 2026, 3:38PM Annual Report FY2526
  • Rekvina Laboratories - Shareholder's Meeting To Be Held On 29.09.2026 Through Online Mode

    3 Sep 2026, 3:33PM Shareholder's Meeting to be held on 29.09.2026 through online mode
  • Rekvina Laboratories - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer

    2 Sep 2026, 7:37PM Resignation of Mr. Deepak Khandelwal from the position of Company Secretary and Compliance Officer
  • Rekvina Laboratories - Shareholder's Meeting To Be Held On 29.09.2026 Through Online Mode

    3 Sep 2026, 3:33PM Shareholder's Meeting to be held on 29.09.2026 through online mode
  • Rekvina Laboratories - Shareholder's Meeting To Be Held On 29.09.2026 Through Online Mode

    3 Sep 2026, 3:33PM Shareholder's Meeting to be held on 29.09.2026 through online mode
  • Rekvina Laboratories - Shareholder's Meeting To Be Held On 29.09.2026 Through Online Mode

    3 Sep 2026, 3:33PM Shareholder's Meeting to be held on 29.09.2026 through online mode
  • Rekvina Laboratories - Shareholder's Meeting To Be Held On 29.09.2026 Through Online Mode

    3 Sep 2026, 3:33PM Shareholder's Meeting to be held on 29.09.2026 through online mode
  • Rekvina Laboratories - Shareholder's Meeting To Be Held On 29.09.2026 Through Online Mode

    3 Sep 2026, 3:33PM Shareholder's Meeting to be held on 29.09.2026 through online mode
  • Rekvina Laboratories has submitted to BSE the Shareholding Pattern for the Period Ended August 12, 2026

    20 Aug 2026, 6:30PM As of August 2026, 77.00% is owned by Indian Promoters and 23.00% by Public. <p align=justify> Top five Promoters holding highest number of shares of
  • Rekvina Laboratories - Clarification On Price Movement

    14 Aug 2026, 7:37PM Clarification on Price Movement
  • Rekvina Laboratories - FINANCIAL RESULTS QTR1

    13 Aug 2026, 3:56PM FINANCIAL RESULT QTR1
  • Rekvina Laboratories - Board Meeting Outcome for OUTCOME OF BOARD MEETING

    13 Aug 2026, 3:48PM OUTCOME OF BOARD MEETING
  • Rekvina Laboratories - Clarification sought from Rekvina Laboratories Ltd

    12 Aug 2026, 6:00PM The Exchange has sought clarification from Rekvina Laboratories Ltd on August 12, 2026 with reference to significant movement in price, in order to en
  • Rekvina Laboratories - Announcement under Regulation 30 (LODR)-Allotment

    12 Aug 2026, 5:27PM Allotment of Equity Shares on Preferential basis
  • Rekvina Laboratories - Board Meeting Intimation for Consideration Of Unaudited Financial Result For The Quarter Ended 30Th Ju

    1 Aug 2026, 12:27PM Rekvina Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider
  • Rekvina Laboratories - Announcement under Regulation 30 (LODR)-Open Offer - Updates

    1 Aug 2026, 12:18PM Post offer Newspaper Annoucement
  • Rekvina Laboratories - Post Offer Advertisement

    31 Jul 2026, 1:52PM Vivro Financial Services Pvt Ltd (\Manager to the Open Offer\) has submitted to BSE a copy of Post Offer Advertisement in accordance with Regulation 1
  • Rekvina Laboratories has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    21 Jul 2026, 5:00PM As of June 2026, 41.30% is owned by Indian Promoters and 58.70% by Public. <p align=justify> Top three Promoters holding highest number of shares of R
  • Rekvina Laboratories - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    15 Jul 2026, 7:51PM Compliance Certificate under Reg 74(5) of SEBI (DP) Regulation 2018
  • Rekvina Laboratories - Announcement under Regulation 30 (LODR)-Open Offer - Updates

    30 Jun 2026, 6:50PM Open Offer Update
  • Rekvina Laboratories - Pre-Offer Advertisement & Corrigendum to Detailed Public Statement

    30 Jun 2026, 6:36PM Vivro Financial Services Pvt Ltd (\Manager to the Open Offer\) has submitted to BSE a copy of Pre-Offer Advertisement in accordance with Regulation 18
  • Rekvina Laboratories - Updates on Open Offer

    25 Jun 2026, 2:28PM Vivro Financial Services Pvt Ltd (\Manager to the Open Offer\) has submitted to BSE a copy of Recommendations of the Committee of Independent Director
  • Rekvina Laboratories - Announcement under Regulation 30 (LODR)-Open Offer - Updates

    25 Jun 2026, 2:12PM Newspaper Advertisement
  • Rekvina Laboratories - Announcement under Regulation 30 (LODR)-Open Offer - Updates

    24 Jun 2026, 1:12PM Recommendations of the Committee of Independent Directors of Company under Regulation 26(7) of SEBI (SAST) Regulation, 2011
  • Rekvina Laboratories - Announcement under Regulation 30 (LODR)-Open Offer - Updates

    23 Jun 2026, 2:27PM We wish to inform you that the company has received a copy of the letter of offer issued by Vivro Financial Services Private Limited in relation to op
  • Rekvina Laboratories - Letter of Offer

    23 Jun 2026, 1:40PM Vivro Financial Services Pvt Ltd (\Manager to the Open Offer\) has submitted to BSE a copy of Letter of Offer for the attention of the Equity Sharehol

Key fundamentals

Evaluate the intrinsic value of Rekvina Laboratories Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 0.2445 -0.0853 -0.0032 0.0131 0.0139
Liabilities 0.2445 -0.0853 -0.0032 0.0131 0.0139
Equity 3.014 3.014 3.014 3.014 3.014
Gross Profit -0.2547 -0.1371 -0.0164 -0.004 -0.0754
Net Profit -0.2547 -0.1371 -0.0164 -0.0007 -0.0788
Cash From Operating Activities -0.5943 -0.1919 -0.0002 0.0099 -0.0399
NPM(%) -20.12 0 0 0 0
Revenue 1.2654 0 0 0 0
Expenses 1.5201 0.1371 0.0164 0.004 0.0754
ROE(%) 18.88 10.16 1.21 0.05 5.84

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Rekvina Laboratories Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 863.00 -0.52 21.76 30.72 -26.19 0.58
Lotus Eye Hospital and Institute Ltd 109.90 -0.68 1563.29 111.95 0.39 0.00
Bharat Immunological and Biologicals Corporation Ltd 15.42 0.72 0.00 232.44 -39.50 0.00
Astec Lifesciences Ltd 552.30 -3.93 0.00 119.94 -363.14 0.00

Company Info

The Indian pharmaceutical industry is at the center stage in the global pharmaceutical arena and Rekvina is at the forefront in delivering the India centric advantages to the advanced and developing countries of the world. From a small domestic company at inception in middle of 80's, Rekvina has grown formidably to be an integrated, Indian pharmaceutical company with sales in excess of twenty crore INR. It is with the unwavering 'dedication' and the 'Will to Win ' of Team Rekvina across India that the Company have traversed this journey so far. The Company is so committed to provide quality medication at affordable prices to the patients with a view to help bring down the healthcare costs & confident that our efforts would see the Company grow from strength to strength in the global space in the years to come. Whilst company continue to enhance the momentum of products, also accelerating drug discovery program through collaborations and alliances. As Company move ahead & determined to capitalize on the new opportunities based on our strong fundamentals of innovation, entrepreneurship and aggressive marketing. Still the Company remain committed to actively pursue strategy of growth through organic and inorganic means. Today, Company is well prepared to be amongst the top 100 pharmaceutical companies of India and attain a size of 100 crore INR by 2020. As It stepped into the next phase, driven by our ambition, willing to invest in the growth of our people and business, marching towards the new horizon of global leadership. Milestone of the Company  This company has introduced the concept of Dispersible Kid Tablets for Pediatric patients. Company's unique formulations include Prestigious product "REKFA", (Essential Fatty Acid - in Capsule, Cream & Pediatric Drop). Enthused by the market response, the group introduced many more specialised quality products for Human Health Care. It has introduced highly specialized products for Gynecological specialty and finally introduced prestigious product REKSEAL (Enbucrilate - n-Butylcyanoacrylate), the Tissue Adhesive which has further added a feather of success to the cap and lead to the introduction of still more specialised products. Vision Rekvina To emerge as a global Pharma player. To enter the advanced markets of the world with a sustained presence over the long-term. Planning proactively to introduce the right products at the right time with the support of WHO-GMP and other quality certifications. Introducing products in the gynecological disorders and surgical therapeutic segments. Entering advanced markets with New Chemical Entities (NCE). Maintaining the highest standards of current Good Manufacturing Practices (cGMP / Revised Schedule-M). Delivering customer value through a high quality of technical support, analytical data, technical documentation and regulatory compliance. Generating a cost advantage for its customers and the company through process innovation of raw material efficiency, innovative R&D and engineering. Making operations safe and reliable by minimizing waste, implementing effective waste treatment and protecting the environment. Mission Rekvina While committing to an on-going improvement in performance revolving around effective customer management, Company maintains: The highest levels of integrity in business conduct, A strong sense of public responsibility. To promote and provide an open and participative work environment with growth opportunities for all employees.  2014 -Rekvina Laboratories has splits its face value from Rs 10/- to 5/-

The Indian pharmaceutical industry is at the center stage in the global pharmaceutical arena and Rekvina is at the forefront in delivering the India centric advantages to the advanced and developing countries of the world. From a small domestic company at inception in middle of 80's, Rekvina has grown formidably to be an integrated, Indian pharmaceutical company with sales in excess of twenty crore INR. It is with the unwavering 'dedication' and the 'Will to Win ' of Team Rekvina across India that the Company have traversed this journey so far. The Company is so committed to provide quality medication at affordable prices to the patients with a view to help bring down the healthcare costs & confident that our efforts would see the Company grow from strength to strength in the global space in the years to come. Whilst company continue to enhance the momentum of products, also accelerating drug discovery program through collaborations and alliances. As Company move ahead & determined to capitalize on the new opportunities based on our strong fundamentals of innovation, entrepreneurship and aggressive marketing. Still the Company remain committed to actively pursue strategy of growth through organic and inorganic means. Today, Company is well prepared to be amongst the top 100 pharmaceutical companies of India and attain a size of 100 crore INR by 2020. As It stepped into the next phase, driven by our ambition, willing to invest in the growth of our people and business, marching towards the new horizon of global leadership. Milestone of the Company  This company has introduced the concept of Dispersible Kid Tablets for Pediatric patients. Company's unique formulations include Prestigious product "REKFA", (Essential Fatty Acid - in Capsule, Cream & Pediatric Drop). Enthused by the market response, the group introduced many more specialised quality products for Human Health Care. It has introduced highly specialized products for Gynecological specialty and finally introduced prestigious product REKSEAL (Enbucrilate - n-Butylcyanoacrylate), the Tissue Adhesive which has further added a feather of success to the cap and lead to the introduction of still more specialised products. Vision Rekvina To emerge as a global Pharma player. To enter the advanced markets of the world with a sustained presence over the long-term. Planning proactively to introduce the right products at the right time with the support of WHO-GMP and other quality certifications. Introducing products in the gynecological disorders and surgical therapeutic segments. Entering advanced markets with New Chemical Entities (NCE). Maintaining the highest standards of current Good Manufacturing Practices (cGMP / Revised Schedule-M). Delivering customer value through a high quality of technical support, analytical data, technical documentation and regulatory compliance. Generating a cost advantage for its customers and the company through process innovation of raw material efficiency, innovative R&D and engineering. Making operations safe and reliable by minimizing waste, implementing effective waste treatment and protecting the environment. Mission Rekvina While committing to an on-going improvement in performance revolving around effective customer management, Company maintains: The highest levels of integrity in business conduct, A strong sense of public responsibility. To promote and provide an open and participative work environment with growth opportunities for all employees.  2014 -Rekvina Laboratories has splits its face value from Rs 10/- to 5/-

Parent Organisation

Rekvina Laboratories Ltd.

Founded

01/11/1988

Managing Director

Mr.Amit Mukesh Shah

NSE Symbol

FAQ